New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.

摘要: Pancreatic cancer remains a major therapeutic challenge in 2008. The annual incidence rate of pancreatic is almost identical to the mortality rate; approximately 37,000 new cases are diagnosed each year United States, and 33,000 patients die from this disease. Poor prognosis has been attributed an inability diagnose at early stage. Majority have advanced time diagnosis. Advanced disease associated with dismal outcome, median survival 3-6 months. author summarizes key studies presented 44th ASCO Annual Meeting, Chicago, IL, USA, May 30 - June 3, CONKO-001 study: final results randomized, prospective, multicenter phase III trial adjuvant chemotherapy gemcitabine vs. observation resected cancer. E4201 randomized study combination radiation therapy alone localized, unresectable AViTA double-blind, placebo-controlled, evaluate efficacy safety adding bevacizumab erlotinib metastatic CONKO-003 gemcitabine-refractory